Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pancreatic cancer: how can we progress?

Literature DB >> 8422277

Pancreatic cancer: how can we progress?

E S Casper¹.

Abstract

Entities: Disease

Mesh：

Substances：
Cisplatin

Year: 1993 PMID： 8422277 DOI： 10.1016/0959-8049(93)90167-e

Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage.

Authors: Miquel Porta; Xavier Fabregat; Núria Malats; Luisa Guarner; Alfredo Carrato; Ana de Miguel; Laura Ruiz; Manuel Jariod; Sergi Costafreda; Susana Coll; Juan Alguacil; Josep M Corominas; Ricard Solà; Antonio Salas; Francisco X Real
Journal: Clin Transl Oncol Date: 2005-06 Impact factor: 3.405

2. Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors:
Journal: Int J Pancreatol Date: 1994 Oct-Dec

3. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.

Authors: Jason E Faris; Jamie Arnott; Hui Zheng; David P Ryan; Thomas A Abrams; Lawrence S Blaszkowsky; Jeffrey W Clark; Peter C Enzinger; Aram F Hezel; Kimmie Ng; Brian M Wolpin; Eunice L Kwak
Journal: Invest New Drugs Date: 2011-07-29 Impact factor: 3.850

Review 8. Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.

Authors: D D Von Hoff; A L Goodwin; L Garcia
Journal: Br J Cancer Date: 1998 Impact factor: 7.640

8 in total

Pancreatic cancer: how can we progress?

1. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage.

2. Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

3. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer.

4. Celiac artery adjuvant chemotherapy. Results of a prospective trial.

5. Radioimmunolocalization of human pancreatic carcinoma xenograft by 99mTc-labeled YPC3 monoclonal antibody.

6. The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene.

7. A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.

Review 8. Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.